SPONSORS
PLATINUM SPONSOR
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.
Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
For more information, visit www.takeda.com.
SILVER SPONSOR
CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000 people.
Al Khayyat Investments (AKI) is a diversified Emirati family-owned holding company with a portfolio spanning healthcare, consumer, contracting, retail, veterinary & environmental, fitness & leisure, automotive, logistics and manufacturing.
Within its healthcare portfolio, AKI Pharma works with leading global partners to bring high-quality, innovative therapies and healthcare solutions to patients and healthcare professionals, with expertise across rare diseases, hematology, immunology, and other areas of high unmet medical need.
Through its partnership with Grifols, AKI Pharma supports access to specialized therapies while advancing disease awareness and management for patients requiring complex and long-term care. Its portfolio includes solutions addressing conditions such as primary immunodeficiencies, immune thrombocytopenia and other rare and complex diseases.
Through long-term partnerships, scientific collaboration and healthcare education, AKI Pharma aims to contribute to better outcomes for patients while supporting the continued advancement of specialised care across the region.
EXHIBITOR
Inpharmus is a commercial-stage biopharmaceutical commercialization company. It connects global biopharma originators with high-potential, complex emerging markets across the MERAT region—encompassing the Middle East, Russia & CIS, North Africa, and Türkiye. Led by CEO İsmet İnce, the company operates regional hubs in Istanbul, Dubai, and Moscow.
Inpharmus specializes in accelerating patient access to treatments for complex medical conditions, focusing primarily on:
Therapeutic Specialties: Pediatric and adult oncology, hematology, rare metabolic diseases, neurology, and immunology.
End-to-End Execution: Managing the full commercialization pipeline—including regulatory navigation, Named Patient Access (NPA) programs, market access, medical affairs, and compliant commercialization under international standards (ICH Q10, EFPIA, OFAC).
Selective Model: Focusing on high-value innovator therapies with significant regional revenue potential through its signature "Speed & Star" provider engagement strategy.